← All presentations

8 slides

Why does consolidated chain growth mask stockouts in regional markets?

The rapid expansion of major chains requires looking beyond consolidated revenue and examining actual availability per point of sale.

Why does consolidated chain growth mask stockouts in regional markets?

The rapid expansion of major chains requires looking beyond consolidated revenue and examining actual availability per point of sale.

Part 1

The continuous expansion of the pharmaceutical retail sector and the accelerated opening of new stores create a scenario of apparent prosperity for manufacturers and brand owners. In consolidated figures, sell-in numbers show growth, and capillarity seems guaranteed.

Part 2

The pace of openings and logistical capillarity define market access. It is entirely true that large chains shape distribution dynamics and bring products closer to the consumer. The hidden premise, however, is assuming that aggregate revenue growth means execution and availability in each pharmacy are resolved homogeneously.

Part 3

### The abyss between capillarity and actual presence

At this point, it is necessary to separate two concepts that are often treated as synonyms: a chain's store opening volume and effective presence with active SKU availability per point of sale.

Part 4

The mechanism is clear. Chains undergoing accelerated expansion test new markets and adjust local inventories in a decentralized manner. When the sales team relies solely on consolidated reports and analyses based exclusively on sell-in, the warning sign arrives too late.

### Adjusting the focus of commercial execution

Part 5

Resolving this mismatch requires changing how the company reads the channel. Instead of managing the portfolio through regional averages or generic coverage goals, the priority becomes identifying where stockouts, stockout risks, or turnover drops occur by SKU, city, and point of sale.

Part 6

Intelligence tools like Dinn Stock fulfill this exact role by clearly pointing out where there is a lack or risk of availability, prioritizing action by chain and location.

Part 7

Pharmaceutical commercial execution stops being guided by subjective field perceptions and begins to respond to structured signals from the channel.

Read the full article →

Turn data into decisions

Dinn shows where pharmacies lack the product, what changed and where to act first, with source and confidence.

Other presentations